Prognosis of patients hospitalized with a diagnosis of COVID-19 pneumonia in a tertiary hospital in Turkey

Abstract

BACKGROUND: SARS-CoV2/COVID-19 emerged in China and caused a global pandemic in 2020. The mortality rate has been reported to be between 0% and 14.6% in all patients. In this study, we determined the clinical and laboratory parameters of COVID-19 related morbidity and mortality in our hospital. OBJECTIVES: Investigate the relationship between demographic, clinical, and laboratory parameters on COVID-19-related morbidity and mortality. DESIGN: Retrospective observational study. SETTINGS: Tertiary care hospital. PATIENTS AND METHODS: Patients diagnosed with COVID-19 pneumonia from March until the end of December were included in the study. MAIN OUTCOME MEASURES: The relationship between demographic, clinical, and laboratory parameters and the morbidity and mortality rates of patients diagnosed with COVID-19. SAMPLE SIZE: 124 patients RESULTS: The mortality rate was 9.6% (12/124). Coronary artery disease ( P <.0001) diabetes mellitus ( P =.04) fever (>38.3°C) at presentation ( P =.04) hypertension ( P <.0001), and positive smoking history ( P <.0001) were significantly associated with mortality. Patients who died were older, had a higher comorbid disease index, pneumonia severity index, fasting blood glucose, baseline serum creatinine, D-dimer, and had lower baseline haemoglobin, SaO 2 , percentage of lymphocyte counts and diastolic blood pressure. Patients admitted to the ICU were older, had a higher comorbidity disease index, pneumonia severity index, C-reactive protein, WBC, D-dimer, creatinine, number of antibiotics used, longer O 2 support duration, lower hemoglobin, lymphocyte (%), and baseline SaO 2 (%). CONCLUSIONS: Our results were consistent with much of the reported data. We suggest that the frequency, dosage, and duration of steroid treatment should be limited. LIMITATIONS: Low patient number, uncertain reason of mortality, no standard treatment regimen, limited treatment options, like ECMO. CONFLICT OF INTEREST: None.

Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics

“…Although the frequency of empirical antibiotic use may differ between studies, they are generally much lower compared to our results. This is compatible with the generally higher empiric antibiotic use in daily clinical practice in Turkey ( 3 , 13 , 14 ).…”

Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19

“…Although male gender was significant in the univariate analysis of mortality, it lost its significance in the multivariate analysis. In studies evaluating inpatients with COVID-19 in Turkey, increasing age is observed to be one of the significant risk factors for mortality (Kokturk et al 2021 ; Medetalibeyoglu et al 2020 ; Birtay et al 2021 ). Research results from different countries are similar.…”

Olfactory disorders in COVID-19 patients as a prognostic factor: a systematic review

“…In different studies, it has also been stated that patients with anosmia had higher regulated levels of lymphocytes and hemoglobin, and lower levels of d -dimer at admission [ 24 , 52 ]. The results also showed a higher hospitalization period, lymphocytes, hemoglobin, and glomerular filtration rate levels and lower d -dimer and C-reactive protein (CRP).…”

“…The results also showed a higher hospitalization period, lymphocytes, hemoglobin, and glomerular filtration rate levels and lower d -dimer and C-reactive protein (CRP). Further changes in these parameters have been associated with a worse prognosis and an indirect measure of the systemic inflammatory response [ 15 , 41 – 46 , 52 ]. Some authors recommended monitoring these parameters in managing COVID-19 patients [ 53 ].…”